{
    "clinical_study": {
        "@rank": "26696", 
        "arm_group": {
            "arm_group_label": "755nm Alexandrite Laser", 
            "arm_group_type": "Experimental", 
            "description": "755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to collect further data on the safety and efficacy of removing\n      unwanted non cosmetic tattoos (including recalcitrant) using a 755nm Alexandrite laser."
        }, 
        "brief_title": "Evaluation of the 755nm Alexandrite for Unwanted Tattoos", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Unwanted, Non Cosmetic, Tattoos", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Is a healthy male or female between 18 and 85 years old.\n\n          2. Has unwanted non-cosmetic tattoo(s) and wishes to undergo laser treatments to remove\n             them.\n\n          3. Is willing to consent to participate in the study.\n\n          4. Is willing to comply with all requirements of the study including being photographed,\n             following post treatment care and attending all treatment and follow up visits.\n\n        Exclusion Criteria:\n\n          1. Is hypersensitive to light exposure.\n\n          2. Has active localized or systemic infection.\n\n          3. Is taking medication(s) for which sunlight is a contraindication.\n\n          4. Has a history of squamous cell carcinoma or melanoma.\n\n          5. Has a history of keloid scarring.\n\n          6. Has used oral isotretinoin (Accutane\u00ae) within 12 months of initial treatment or plans\n             on using during the course of the study. Note: Skin must regain its normal degree of\n             moisture prior to treatment.\n\n          7. Has a history of immunosuppression/immune deficiency disorders (including HIV\n             infection or AIDS) or use of immunosuppressive medications.\n\n          8. Is female and pregnant, has been pregnant within the last 3 months, is currently\n             breast feeding or planning a pregnancy during the study period.\n\n          9. Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine.\n\n         10. Has any other reason determined by the physician to be ineligible to participate in\n             the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842815", 
            "org_study_id": "CYN12-PICO-SK"
        }, 
        "intervention": {
            "arm_group_label": "755nm Alexandrite Laser", 
            "description": "755 nm alexandrite laser for the treatment of unwante, non cosmetic, tattoos.", 
            "intervention_name": "755 nm alexandrite laser", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sacramento", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "95816"
                }, 
                "name": "Laser & Skin Surgery Center of Northern California"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_official": {
            "affiliation": "Cynosure, Inc.", 
            "last_name": "Patricia Krantz", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clearance will be measured using a photographic scale.", 
            "measure": "TATTOO CLEARANCE", 
            "safety_issue": "No", 
            "time_frame": "3 Months post last treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842815"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Cynosure, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cynosure, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}